A 58-year-old man with primary osteoarthritis of the hip is counselled on management options. Regarding the evidence-based pharmacological and non-pharmacological interventions for osteoarthritis, all of the following are recommended first-line approaches EXCEPT:

Explanation

## Evidence-Based Management of Osteoarthritis **Key Point:** Current guidelines emphasize a stepwise, multimodal approach to OA management. However, not all commonly used interventions have robust evidence for disease modification. NEET PG frequently tests the distinction between symptomatic relief and true disease modification. ### First-Line & Recommended Interventions | Intervention | Evidence Level | Role in OA Management | |--------------|----------------|----------------------| | Weight reduction | Strong | Reduces joint load; improves outcomes | | Low-impact exercise | Strong | Maintains mobility, strengthens periarticular muscles | | Topical NSAIDs | Strong | Local pain relief, minimal systemic absorption | | Oral paracetamol | Moderate–Strong | First-line analgesic for mild-moderate pain | | Intra-articular corticosteroids | Moderate | Symptomatic relief in flares; temporary benefit | | **Glucosamine/chondroitin** | **Weak–Conflicting** | **NOT proven to modify disease or slow cartilage loss** | **High-Yield:** The GAIT trial (2006) and subsequent meta-analyses have shown that glucosamine and chondroitin do NOT significantly slow radiographic progression or provide superior pain relief compared to placebo in primary OA. They are NOT disease-modifying agents. ### Why Option 4 is Incorrect **Clinical Pearl:** Glucosamine and chondroitin are heavily marketed and widely used by patients, but evidence does not support their use as disease-modifying osteoarthritis drugs (DMOADs). They may provide modest symptomatic benefit in some patients (placebo effect or individual variation), but they do NOT prevent or slow cartilage degradation. **Warning:** Do not confuse symptomatic benefit with disease modification. A drug that reduces pain is not necessarily slowing structural progression. Glucosamine fails this test. ### Recommended Management Algorithm ```mermaid flowchart TD A[OA Diagnosis]:::outcome --> B[Weight loss + Exercise]:::action B --> C[Pain control needed?]:::decision C -->|Mild| D[Topical NSAID or Paracetamol]:::action C -->|Moderate| E[Oral NSAID + PPI]:::action E --> F[Adequate relief?]:::decision F -->|No| G[Intra-articular corticosteroid]:::action F -->|Yes| H[Continue management]:::action G --> I[Symptomatic relief achieved]:::outcome A --> J[Avoid: Glucosamine/chondroitin as DMOADs]:::urgent ``` ### Intra-Articular Corticosteroids **Key Point:** While not first-line, intra-articular corticosteroid injections are evidence-based for symptomatic relief in moderate-to-advanced OA, particularly during acute flares. They provide temporary benefit (weeks to months) but do not modify disease. [cite:Harrison 21e Ch 297]